CRYO-CELL INTERNATIONAL, INC. (OTCMKTS:CCEL) Files An 8-K Other Events

ME Staff 8-k
-
0
CRYO-CELL INTERNATIONAL, INC. (OTCMKTS:CCEL) Files An 8-K Other Events

CRYO-CELL INTERNATIONAL, INC. (OTCMKTS:CCEL) Files An 8-K Other Events
Item 8.01.

The Board of Directors of Cryo-Cell International, Inc. (the “Company”) has fixed November 21, 2019 as the date for the 2019 Annual Meeting of Stockholders of the Company (the “Annual Meeting”), and has fixed October 21, 2019 as the record date for determining stockholders entitled to notice of and to vote at the Annual Meeting. Stockholders intending to present business or director nominations at the Annual Meeting must submit the notice required by Article II, Section 3 of the Company’s Bylaws (with respect to business other than director nominations) or Article II, Section 10 of the Company’s Bylaws (with respect to director nominations) no later than the 10th calendar day following the day on which public disclosure of the date of the Annual Meeting is first made, which date of public disclosure is October 8, 2019.

A copy of the Company’s Bylaws, as amended, is attached as Exhibit 3.1 to the Current Report on Form 8-K filed with the United States Securities and Exchange Commission on December 11, 2018.


About CRYO-CELL INTERNATIONAL, INC. (OTCMKTS:CCEL)

Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic storage. The Company’s segments include cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacture of Prepacyte CB units, the processing technology used to process umbilical cord blood stem cells. The Company, in combination with its global affiliates, stores over 300,000 cord blood and cord tissue specimens around the world. The specimens are stored in commercially available cryogenic storage units at the facility in Oldsmar, Florida. The Company offers the cord tissue service in combination with the umbilical cord blood service. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives and other related healthcare professionals.